MX2024002539A - Enzimas con dominios ruvc. - Google Patents
Enzimas con dominios ruvc.Info
- Publication number
- MX2024002539A MX2024002539A MX2024002539A MX2024002539A MX2024002539A MX 2024002539 A MX2024002539 A MX 2024002539A MX 2024002539 A MX2024002539 A MX 2024002539A MX 2024002539 A MX2024002539 A MX 2024002539A MX 2024002539 A MX2024002539 A MX 2024002539A
- Authority
- MX
- Mexico
- Prior art keywords
- enzymes
- ruvc domains
- ruvc
- domains
- variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163237791P | 2021-08-27 | 2021-08-27 | |
| US202163245629P | 2021-09-17 | 2021-09-17 | |
| US202163252956P | 2021-10-06 | 2021-10-06 | |
| US202163282909P | 2021-11-24 | 2021-11-24 | |
| US202263316895P | 2022-03-04 | 2022-03-04 | |
| US202263319681P | 2022-03-14 | 2022-03-14 | |
| US202263322944P | 2022-03-23 | 2022-03-23 | |
| US202263369858P | 2022-07-29 | 2022-07-29 | |
| PCT/US2022/041755 WO2023028348A1 (en) | 2021-08-27 | 2022-08-29 | Enzymes with ruvc domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002539A true MX2024002539A (es) | 2024-03-19 |
Family
ID=85323459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002539A MX2024002539A (es) | 2021-08-27 | 2022-08-29 | Enzimas con dominios ruvc. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12435323B2 (enExample) |
| EP (1) | EP4392561A4 (enExample) |
| JP (1) | JP2024533940A (enExample) |
| KR (1) | KR20240049306A (enExample) |
| CN (1) | CN119452085A (enExample) |
| AU (1) | AU2022335499A1 (enExample) |
| CA (1) | CA3225082A1 (enExample) |
| MX (1) | MX2024002539A (enExample) |
| WO (1) | WO2023028348A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022335499A1 (en) | 2021-08-27 | 2024-02-22 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| AU2023276763A1 (en) | 2022-05-25 | 2024-12-12 | Metagenomi Therapeutics, Inc. | Supplementation of liver enzyme expression |
| CA3267752A1 (en) * | 2022-09-16 | 2024-03-21 | Alia Therapeutics Srl | ENQP TYPE II CAS PROTEINS AND THEIR APPLICATIONS |
| WO2025097031A1 (en) * | 2023-11-02 | 2025-05-08 | Metagenomi, Inc. | Compositions and methods for cell therapy |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| PL3360964T3 (pl) | 2012-12-06 | 2020-03-31 | Sigma-Aldrich Co. Llc | Modyfikacja i regulacja genomu oparta na crispr |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| WO2015066119A1 (en) | 2013-10-30 | 2015-05-07 | North Carolina State University | Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| WO2015161276A2 (en) | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| EP4464338A3 (en) | 2014-11-07 | 2025-02-12 | Editas Medicine, Inc. | Systems for improving crispr/cas-mediated genome-editing |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| AU2016243583B2 (en) * | 2015-03-27 | 2022-03-10 | President And Fellows Of Harvard College | Modified T cells and methods of making and using the same |
| CN107921148A (zh) | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| AU2016263026A1 (en) | 2015-05-15 | 2017-11-09 | Pioneer Hi-Bred International, Inc. | Guide RNA/Cas endonuclease systems |
| WO2016196655A1 (en) | 2015-06-03 | 2016-12-08 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
| US20160362667A1 (en) | 2015-06-10 | 2016-12-15 | Caribou Biosciences, Inc. | CRISPR-Cas Compositions and Methods |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| TWI906646B (zh) | 2015-06-18 | 2025-12-01 | 美商博得學院股份有限公司 | 降低脫靶效應的ｃｒｉｓｐｒ酶突變 |
| WO2017093969A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| WO2017106414A1 (en) | 2015-12-18 | 2017-06-22 | Danisco Us Inc. | Methods and compositions for polymerase ii (pol-ii) based guide rna expression |
| EP3423580A1 (en) * | 2016-03-04 | 2019-01-09 | Editas Medicine, Inc. | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |
| EP3426780A1 (en) | 2016-03-11 | 2019-01-16 | Pioneer Hi-Bred International, Inc. | Novel cas9 systems and methods of use |
| US20190136230A1 (en) | 2016-05-06 | 2019-05-09 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
| EP3500967A1 (en) | 2016-08-17 | 2019-06-26 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| WO2018041120A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
| JP2019532640A (ja) * | 2016-09-29 | 2019-11-14 | ナントクエスト インコーポレイテッド | 免疫原性が低下したｈｌａクラスｉ欠損ｎｋ−９２細胞 |
| BR112019006388A2 (pt) | 2016-09-30 | 2019-06-25 | Univ California | enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas |
| SG10201913505WA (en) | 2016-10-17 | 2020-02-27 | Univ Nanyang Tech | Truncated crispr-cas proteins for dna targeting |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| CA3048907C (en) | 2017-01-06 | 2023-05-23 | Nantkwest, Inc. | Genetically modified nk-92 cells with decreased cd96/tigit expression |
| SG11201906297QA (en) | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| EP3617311B1 (en) | 2017-03-30 | 2024-11-20 | Kyoto University | Method for inducing exon skipping by genome editing |
| MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| EP3625338A4 (en) | 2017-05-19 | 2021-01-20 | Tsinghua University | CONSTRUCTION OF A MINIMAL SACAS9-CRISPR / CAS SYSTEM FOR GENEDITATION AND TRANSCRIPTION REGULATION, OPTIMIZED BY EXTENDED GUIDE-RNA |
| CN107164377A (zh) | 2017-06-12 | 2017-09-15 | 王小平 | 基于碱基编辑的基因敲除方法及其应用 |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| CN107723275B (zh) * | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| IL317505A (en) | 2017-11-10 | 2025-02-01 | Univ Massachusetts | CRISPR-directed delivery platforms |
| US10253365B1 (en) | 2017-11-22 | 2019-04-09 | The Regents Of The University Of California | Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs |
| EP3724326A1 (en) | 2017-12-11 | 2020-10-21 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| KR102465067B1 (ko) | 2018-02-15 | 2022-11-10 | 시그마-알드리치 컴퍼니., 엘엘씨 | 진핵 게놈 변형을 위한 조작된 cas9 시스템 |
| WO2019165168A1 (en) | 2018-02-23 | 2019-08-29 | Pioneer Hi-Bred International, Inc. | Novel cas9 orthologs |
| CN112040987A (zh) | 2018-03-15 | 2020-12-04 | Ksq治疗公司 | 用于改进的免疫疗法的基因调控组合物和方法 |
| CA3094468A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| AU2019252925A1 (en) | 2018-04-13 | 2020-07-30 | Sigma-Aldrich Co. Llc. | Modification of immune-related genomic loci using paired CRISPR nickase ribonucleoproteins |
| WO2020041120A1 (en) | 2018-08-20 | 2020-02-27 | Massachusetts Institute Of Technology | Robotic manipulation of objects using external contacts |
| WO2020055941A1 (en) | 2018-09-13 | 2020-03-19 | Excision Biotherapeutics, Inc. | Compositions and methods for excision with single grna |
| CN110904045A (zh) | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| CN113227374A (zh) | 2018-10-16 | 2021-08-06 | 因特利亚治疗公司 | 用于免疫疗法的组合物和方法 |
| UY38427A (es) * | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
| EP3911735A4 (en) | 2019-01-16 | 2023-07-12 | Beam Therapeutics, Inc. | MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| US20220220460A1 (en) | 2019-02-14 | 2022-07-14 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| WO2021226363A1 (en) | 2020-05-08 | 2021-11-11 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| CA3241703C (en) * | 2019-02-14 | 2026-02-24 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| US20220298494A1 (en) | 2019-02-14 | 2022-09-22 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| PE20211959A1 (es) * | 2019-02-15 | 2021-09-30 | Editas Medicine Inc | Celulas asesinas naturales (nk) modificadas para inmunoterapia |
| JP2020154564A (ja) | 2019-03-19 | 2020-09-24 | 富士通株式会社 | 学習方法、学習プログラムおよび学習装置 |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| WO2021097118A1 (en) | 2019-11-12 | 2021-05-20 | The Broad Institute, Inc. | Small type ii cas proteins and methods of use thereof |
| WO2021202559A1 (en) | 2020-03-31 | 2021-10-07 | Metagenomi Ip Technologies, Llc | Class ii, type ii crispr systems |
| WO2021202568A1 (en) | 2020-03-31 | 2021-10-07 | Metagenomi Ip Technologies, Llc | Class ii, type ii crispr systems |
| EP4165177A4 (en) | 2020-05-08 | 2024-08-28 | Metagenomi, Inc. | ENZYMES WITH RUVC DOMAINS |
| JP2023540797A (ja) | 2020-09-11 | 2023-09-26 | メタゲノミ，インコーポレイテッド | 塩基編集酵素 |
| CN112126661B (zh) | 2020-09-30 | 2022-07-22 | 上海中医药大学 | 一种高效敲除nk细胞中tigit基因的方法 |
| JP2023546671A (ja) | 2020-10-23 | 2023-11-07 | ザ・ブロード・インスティテュート・インコーポレイテッド | 再プログラム可能なｉｓｃｂヌクレアーゼ及びその使用 |
| WO2022132765A1 (en) * | 2020-12-14 | 2022-06-23 | Emendobio Inc. | Biallelic knockout of b2m |
| CA3205865A1 (en) * | 2021-01-22 | 2022-07-28 | Brian C. Thomas | Novel engineered and chimeric nucleases |
| JP2024515936A (ja) | 2021-03-19 | 2024-04-11 | メタゲノミ，インク． | Ｃａｓ酵素を用いたマルチプレックス編集 |
| KR20240004618A (ko) | 2021-04-30 | 2024-01-11 | 메타지노미, 인크. | Ruvc 도메인을 갖는 효소 |
| AU2022335499A1 (en) | 2021-08-27 | 2024-02-22 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| AU2022396533A1 (en) | 2021-11-24 | 2024-05-02 | Metagenomi Therapeutics, Inc. | Endonuclease systems |
| EP4437095A1 (en) | 2021-11-24 | 2024-10-02 | Metagenomi, Inc. | Endonuclease systems |
| AU2023235279A1 (en) * | 2022-03-14 | 2024-10-03 | Metagenomi Therapeutics, Inc. | Engineered and chimeric nucleases |
-
2022
- 2022-08-29 AU AU2022335499A patent/AU2022335499A1/en active Pending
- 2022-08-29 KR KR1020247008513A patent/KR20240049306A/ko active Pending
- 2022-08-29 WO PCT/US2022/041755 patent/WO2023028348A1/en not_active Ceased
- 2022-08-29 CA CA3225082A patent/CA3225082A1/en active Pending
- 2022-08-29 CN CN202280062860.0A patent/CN119452085A/zh active Pending
- 2022-08-29 MX MX2024002539A patent/MX2024002539A/es unknown
- 2022-08-29 EP EP22862160.3A patent/EP4392561A4/en active Pending
- 2022-08-29 JP JP2024502432A patent/JP2024533940A/ja active Pending
-
2024
- 2024-02-26 US US18/586,929 patent/US12435323B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024533940A (ja) | 2024-09-18 |
| WO2023028348A1 (en) | 2023-03-02 |
| CN119452085A (zh) | 2025-02-14 |
| EP4392561A4 (en) | 2025-12-24 |
| US12435323B2 (en) | 2025-10-07 |
| EP4392561A1 (en) | 2024-07-03 |
| AU2022335499A1 (en) | 2024-02-22 |
| KR20240049306A (ko) | 2024-04-16 |
| US20240200047A1 (en) | 2024-06-20 |
| CA3225082A1 (en) | 2023-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009886A (es) | Enzimas con dominios ruvc. | |
| MX2024002539A (es) | Enzimas con dominios ruvc. | |
| MX2022014067A (es) | Enzimas con dominios ruvc. | |
| CO2018003168A2 (es) | Moduladores de la expresión de kras | |
| MX2023002913A (es) | Enzimas para edicion de bases. | |
| MX370506B (es) | Método para tratar trastorno de estrés post-traumático. | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| CO2017013065A2 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
| BR112018070133A2 (pt) | dispersão, uso desta e método para a inativação fotodinâmica de micro-organismos | |
| CR20140422A (es) | Composiciones de enzima digestiva estable | |
| MX2023012606A (es) | Enzimas con dominios ruvc. | |
| NI202000085A (es) | Moduladores de la expresión de apol1 | |
| CR20190471A (es) | Moduladores de la expresión de pcsk9 | |
| BR112018074032A2 (pt) | composições e métodos relacionados a construtos de fc manipulados | |
| CO2023015915A2 (es) | Anticuerpos anti-ccr8 | |
| MX2019010759A (es) | Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas. | |
| BR112018071600A2 (pt) | métodos, composições e usos relacionados aos mesmos | |
| MX380677B (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. | |
| BR112016002498A2 (pt) | método para reduzir o teor de ácidos hexenurônicos em uma polpa celulósica química e/ou melhorar o brilho de polpa celulósica química, composição aquosa, e, utilização de uma haloperoxidase | |
| MX2017014213A (es) | Penicilina-g acilasas. | |
| MX2020004211A (es) | Mitoflavoscinas: la fijacion como objetivo de enzimas que contienen flavina elimina celulas madre cancerosas (cscs) al inhibir la respiracion mitocondrial. | |
| BR112018071601A2 (pt) | métodos, composições e usos relacionados aos mesmos | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 | |
| BR112017016194A2 (pt) | método | |
| MX2019008096A (es) | Penicilina g acilasas. |